Cyclerion Therapeutics Financials

Trends View

Profitability View

Liquidity View

Fundamentals View

Competition View

Cyclerion Therapeutics Stock Summary

Cyclerion Therapeutics competes with Kronos Bio, Larimar Therapeutics, Addex Therapeutics, Achilles Therapeutics, and Lipella Pharmaceuticals. Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system diseases. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Cyclerion Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people.

Cyclerion Therapeutics Key Financial Ratios

Cyclerion Therapeutics' financial ratios allow both analysts and investors to convert raw data from Cyclerion Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Cyclerion Therapeutics over time and compare it to other companies across industries.

Cyclerion Therapeutics Key Balance Sheet Accounts

Cyclerion Therapeutics Key Income Statement Accounts

Cyclerion Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cyclerion Therapeutics's current stock value. Our valuation model uses many indicators to compare Cyclerion Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cyclerion Therapeutics competition to find correlations between indicators driving Cyclerion Therapeutics's intrinsic value. More Info.Cyclerion Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Cyclerion Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclerion Therapeutics' earnings, one of the primary drivers of an investment's value.

Cyclerion Therapeutics Systematic Risk

Today, most investors in Cyclerion Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cyclerion Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cyclerion Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Cyclerion Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cyclerion Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cyclerion Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Cyclerion Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cyclerion Therapeutics's daily price indicators and compare them against related drivers.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.